The effect of doxycycline on atherogenesis in apoe-knockout mice

Journal of Physiology and Pharmacology

Volumn 62, Issue 2, 2011, Pages 247-250

  Pawlowska, M ^a   Gajda, M ^a   Pyka Fosciak, G ^a   Toton Zuranska, J ^a   Niepsuj, A ^a   Kus, K ^a   Bujak Gizycka, B ^a   Suski, M ^a   Olszanecki, R ^a   Jawien, J ^a   Korbut, R ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Apoe knockout mice; Atherosclerosis; Cholesterol; Doxycycline; Matrix metalloproteinases; Triglycerides

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; DOXYCYCLINE; GELATINASE; MATRIX METALLOPROTEINASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ZYMOGRAPHY;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DOXYCYCLINE; FEMALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 79959334693     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Johnson JL, Fritsche-Danielson R, Behrendt M, et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res 2006; 71: 586-595.
2. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
3. Higashikata T, Yamagishi M, Higashi T, et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method. Atherosclerosis 2006; 185: 165-172.
4. Nikkari ST, Geary RL, Hatsukami T, et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. Am J Pathol 1996; 148: 777-783.
5. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 1120-1125.
6. Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 1998; 12: 114-118.
7. Gapski R, Hasturk H, Van Dyke TE, et al. Systemic MMP inhibition for periodontal wound repair: results of a multicentre randomized-controlled clinical trial. J Clin Periodontol 2009; 36: 149-156.
8. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503-517.
9. Jawien J, Gajda M, Rudling M, et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006; 36: 141-146.
10. Jawien J, Csanyi G, Gajda M, et al. Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Eur J Pharmacol 2007; 556: 129-135.
11. Jawien J, Gajda M, Wolkow P, Zuranska J, Olszanecki R, Korbut R. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2008; 59: 633-639.
12. Toton-Zuranska J, Gajda M, Pyka-Fosciak G, et al. AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2010; 61: 181-183.
13. Shi W, Brown MD, Wang X, et al. Genetic backgrounds but not sizes of atherosclerotic lesions determine medial destruction in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 1901-1906.
14. Back M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010; 52: 410-428.
15. Jawien J, Gajda M, Olszanecki R, Korbut R. BAY x 1005 attenuates atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2007; 58: 583-538.
16. Ryan ME, Ashley RA. How do tetracyclines work? Adv Dent Res 1998; 12: 149-151.
17. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12-26.
18. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23: 483-488.
19. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998; 28: 1082-1093.
20. Zelaszczyk D, Kozlowska H, Baranowska U, et al. Four close bupranolol analogues are antagonists at the lowaffinity state of beta1-adrenoceptors. J Physiol Pharmacol 2009; 60(1): 51-60.
21. Castro MM, Rizzi E, Figueiredo-Lopes L, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-331.
22. Madan M, Bishayi B, Hoge M, Messas E, Amar S. Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atherosclerosis 2007; 190: 62-72.
23. Radwanska A, Dlugokecka J, Wasilewski R, Kaliszan R. Testing conception of engagement of imidazoline receptors in imidazoline drugs effects on isolated rat heart atria. J Physiol Pharmacol 2009; 60: 131-142.
24. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004; 42: 121-131.
25. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13: 333-346.
26. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
27. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004; 6: 112-120.
28. Kus K, Gajda M, Pyka-Fosciak G, et al. The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009; 60: 163-165.